Little-Known Small Cap Could be Just What the Doctor Ordered

Popular Posts: Top 6 Stocks to Buy for NovemberTop 6 Stocks to Buy for OctoberWhat to Do While You Wait for a Correction Recent Posts: 2 Bearish Reversal Signals Warn of a Correction Little-Known Small Cap Could be Just What the Doctor Ordered Fight the Tape and the Fed at Your Own Peril View All Posts

OraSure Technologies (OSUR) — This small-cap company develops, manufactures and markets oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies.

Hot Value Companies To Buy For 2014

Jeffrey Saut of Raymond James mentioned the stock in connection with a recent Wall Street Journal article that noted millions of boomers may get a request to get tested for hepatitis C. Saut said that OSUR has one of the best tests for hepatitis C on the market. And with a potential cure for the disease possibly hitting the market soon, this company could be in a unique position to benefit from the demand for testing.

OSUR formed a bullish saucer, broke through its 200-day moving average and flashed a golden cross at $5.20. The stochastic indicator flashed a buy signal Wednesday, and the stock appears to be under accumulation and in a bull channel. Buy OSUR at the market as a long-term hold.

Click to Enlarge

Will Nike Stock Perform?

With shares of Nike (NYSE:NKE) trading around $61, is NKE an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Nike is engaged in the design, development, and worldwide marketing and selling of footwear, apparel, equipment, accessories and services. The company sells its products to retail accounts, through retail stores and Internet sales, and through a mix of independent distributors and licensees around the world. Nike focuses its product offerings in seven key categories: Running, Basketball, Soccer, Men's Training, Women's Training, Nike Sportswear, and Action Sports. It also markets products designed for kids, as well as for other athletic and recreational uses. Looking around, many consumers and companies are advocating and opting for a lifestyle that involves more outdoor and physical activity. As the fitness and staying active movement sees progress, Nike is a company that is poised to see rising profits. A recent positive earnings report may be the fuel Nike needs to head higher this coming quarter.

T = Technicals on the Stock Chart are Strong

Nike stock has seen a bullish move towards higher prices in recent years. The stock has pulled-back from all-time highs so it may need a bit of time before continuing higher. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Nike is trading between its rising key averages which signal neutral to bullish price action in the near-term.

Best Small Cap Companies To Invest In Right Now

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of Nike options may help determine if investors are bullish, neutral, or bearish.

	Implied Volatility (IV)	30-Day IV Percentile	90-Day IV Percentile
Nike Options	23.47%	16%	14%

What does this mean? This means that investors or traders are buying a very minimal amount of call and put options contracts, as compared to the last 30 and 90 trading days.

	Put IV Skew	Call IV Skew
July Options	Flat	Average
August Options	Flat	Average

As of today, there is an average demand from call buyers or sellers and low demand by put buyers or high demand by put sellers, all neutral to bullish over the next two months. To summarize, investors are buying a very minimal amount of call and put option contracts and are leaning neutral to bullish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Improving Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on Nike’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for Nike look like and more importantly, how did the markets like these numbers?

	2013 Q1	2012 Q4	2012 Q3	2012 Q2
Earnings Growth (Y-O-Y)	28.81%	58.33%	-16.00%	-9.56%
Revenue Growth (Y-O-Y)	3.51%	9.39%	7.37%	9.67%
Earnings Reaction	-0.50%	11.06%	6.16%	-1.12%

Nike has seen improving earnings and rising revenue figures over the last four quarters. From these numbers, the markets have generally been pleased with Nike’s recent earnings announcements.

P = Average Relative Performance Versus Peers and Sector

How has Nike stock done relative to its peers, Under Armour (NYSE:UA), Crocs (NASDAQ:CROX), Deckers Outdoor (NASDAQ:DECK), and sector?

	Nike	Under Armour	Crocs	Deckers Outdoor	Sector
Year-to-Date Return	20.11%	21.74%	13.00%	23.67%	18.75%

Nike has been an avearge relative performer, year-to-date.

Conclusion

Nike offers athletic and fitness related apparel and footwear products to user base that is showing impressive signs of growth. The stock has been on a bullish move higher that has taken it to all-time highs, however, it has now pulled back a bit so may need time before making its next move. Over the last four quarters, investors in the company have generally been pleased as earnings have improved and revenue figures have been on the rise. Relative to its peers and sector, Nike has been an average performer. Look for Nike to OUTPERFORM.

Hot High Tech Companies To Watch For 2014

Check out Jim Cramer's latest trading recommendations on "Action Alerts Plus". (Updates from 10:36 a.m. ET with closing information.)

NEW YORK (TheStreet) -- Here's what Jim Cramer had to say on CNBC's "Squawk on the Street" Monday.

Although Deutsche Bank downgraded Goodyear Tire & Rubber (GT) to hold from buy, Cramer wasn't so sure about it. He said the stock has been red-hot this year. GT plummeted 6.7% to $21.12.

First Horizon National (FHN) missed on earnings estimates. Cramer said he can't figure out what's wrong with the company but he does like the stock. FHN fell 1.2% to $10.88. Cramer said he's surprised by Cimarex Energy's (XEC) current stock price, saying the company is "worth a lot more than it's selling for." XEC dropped 1.3% to $108.99. Cramer suggested commodity food companies are doing better now in the market, and reminded investors Dean Foods (DF) is big in milk. DF rose 1% to $18.42. Schlumberger's (SLB) orders in the Middle East and Pacific continue to drive the stock higher, Cramer said. SLB was 1% lower to $93.48. Investors are still worried about Allergan (AGN) and its patents, but Cramer said he likes the stock and CEO Dave Pyott is "money in the bank." AGN was flat at $90.47. To sign up for Jim Cramer's free Booyah! newsletter, with all of his latest articles and videos, please click here. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell

Hot High Tech Companies To Watch For 2014: Ucore Uranium Inc (UCU.V)

Ucore Rare Metals Inc., a junior exploration company, engages in the exploration and development of rare earth element (REE) and uranium properties. The company�s flagship property includes the Bokan Mountain/Dotson Ridge REE property comprising 422 claims located on the southern end of the Prince of Wales Island in southern Alaska. It also has various properties in Ray Mountains, Alaska; Elliott Lake, Ontario; Greater Newfoundland; Sandybeach Lake, Nunavut; and Lost Pond, Newfoundland. The company was formerly known as Ucore Uranium Inc. and changed its name to Ucore Rare Metals Inc. in June 2010. Ucore Rare Metals Inc. is headquartered in Hammonds Plains, Canada.

Hot High Tech Companies To Watch For 2014: Orion Metals Limited(ORM.AX)

Orion Metals Limited engages in the exploration and evaluation of mineral resource properties in Australia. It primarily explores for gold; uranium; heavy rare earth elements comprising dysprosium, ytterbium, and erbium; and other rare earth and tech metals in Western Australia and Queensland. The company was formerly known as Queensland Gold and Minerals Limited and changed its name to Orion Metals Limited in 2009. Orion Metals Limited was founded in 2001 and is based in East Brisbane, Australia.

Top Casino Companies For 2014: LyondellBasell Industries NV(LYB)

LyondellBasell Industries N.V. manufacturers and sells chemicals and polymers, refines crude oil, produces gasoline blending components, and develops and licenses technologies for production of polymers. The company?s Olefins and Polyolefins segment offers olefins, including ethylene, propylene, and butadiene; aromatics, such as benzene and toluene; polyolefins, which comprise polypropylene (PP), high-density polyethylene, low-density polyethylene, and linear low-density polyethylene; specialty polyolefins, including catalloy process resins, PP compounds, and polybutene-1 resins; and ethylene derivatives, which comprise ethanol. Its Intermediates and Derivatives segment provides propylene oxide (PO); PO co-products, including styrene monomers and TBA derivative isobutylene; PO derivatives, such as propylene glycol, propylene glycol ethers, and butanediol; acetyls, such as methanol, acetic acid, and vinyl acetate monomers; ethylene derivatives, which comprise ethylene oxide , ethylene glycol, and ethylene glycol ethers; and flavor and fragrance chemicals. The company?s Refining and Oxyfuels segment offers gasoline and components, ultra low sulfur diesel, jet fuel, and lube oils; diesel, feedstock, fuel oil, gasoline, and bitumen; and gasoline blending components, including methyl tertiary butyl ether, ethyl tertiary butyl ether, and alkylate. Its Technology segment develops and licenses polyolefin and other process technologies. This segment also develops, manufactures, and sells polyolefin catalysts, as well as provides technology services, which comprise safety reviews, training and start-up assistance, engineering services for process and product improvements, and manufacturing troubleshooting. LyondellBasell Industries N.V. has operations in the Americas, Europe, Asia, and internationally. The company was founded in 2005 and is based in Rotterdam, Netherlands. LyondellBasell Industries N.V. is a subsidiary of Prochemie GmbH.

Advisors' Opinion:

• [By Chad Tracy]

  In a classic contrarian move, he purchased more shares of troubled plastics-maker LyondellBasell Industries (NYSE: LYB), even as the company was sliding toward bankruptcy.

• [By Chad Tracy]

  TransCanada is not the only company that stands to profit from the possible Keystone XL approval. Refiners such as Valero and LyondellBasell Industries (NYSE: LYB), as well as construction companies Deere & Co. (NYSE: DE) and Quanta Services (NYSE: PWR) all stand to gain if Keystone XL gets the green light.

• [By Taylor Muckerman]

  Along with Dow, DuPont (NYSE: DD  ) and LyondellBasell (NYSE: LYB  ) are two companies that have used this access to their advantage. All three will be reporting earnings this week. Motley Fool analyst Taylor Muckerman expects margins to remain relatively high, but the growth we have seen over the past few years might begin to slow. In addition, he touches on some of the future market dynamics that will likely roll out as the available infrastructure continues to increase. Details can be found in the video below.

• [By Tyler Crowe]

  This cheap feedstock has sent production up over one-third in the past five years, and has given a nice pad to chemical company earnings. LyondellBassell (NYSE: LYB  ) reported that 2012 was a record year in terms of earnings despite a 6% drop in revenue. These kinds of results have resulted in a mad rush to increase�capacity. The entire industry has plans to spend about $30 billion in new plants to take advantage of cheap feedstock. Dow personally is looking to invest $1.7 billion to build what would be the company's largest ethylene facility and would increase the company's ethylene capacity by 1.5 million tons per year. With so much invested in cheap natural gas, it should come as no surprise that the company will look to protect that position for as long as possible.�

Hot High Tech Companies To Watch For 2014: Vitec Group(VTC.L)

The Vitec Group plc, together with its subsidiaries, provides products and services for the broadcast, photographic, military, aerospace, and government markets worldwide. It operates in three divisions: Imaging and Staging, Videocom, and Services. The Imaging and Staging division engages in the design, manufacture, and distribution of equipment and accessories for professionals and amateurs in photography, video, and events fields. This division offers photo, video, and lighting support products; and stage and lighting systems, as well as distributes products for the photographic, video, cine, and lighting production markets. The Videocom division designs and distributes equipment principally for professionals engaged in producing and transporting video content for the media industries, such as broadcast, film, live events, and education, as well as for the military, aerospace, and government markets. It offers bags, camera accessories, lighting products, microwave system s, mobile power systems, prompters, and camera support equipment, as well as equipment rental services. The Services division provides equipment rental, workflow design, and technical support services for camera, video, audio, fiber optic, and wireless technology used by television production teams and film crews. It offers production equipment rental, used production equipment sales, maintenance services, event systems and services, and audio services and sales, as well as fiber optic system design, installation, and maintenance services. The company was formerly known as Vitec Group plc and changed its name to The Vitec Group plc in 2001. The Vitec Group plc was founded in 1910 and is headquartered in Kingston upon Thames, the United Kingdom.

Hot High Tech Companies To Watch For 2014: Myriad Genetics Inc (MYGN.O)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company h ad launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recu rrence and measure a patient's exposure to drug therapy to! e! nsure optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

< p>Companion Diagnostic Services and Other Revenue

! Throug! h Myriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeu tic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Hot High Tech Companies To Watch For 2014: CarMax Inc(KMX)

CarMax, Inc., through its subsidiaries, operates as a retailer of used vehicles in the United States. It also sells vehicles that do not meet its retail standards to licensed dealers through on-site wholesale auctions, as well as sells new vehicles under franchise agreements. In addition, the company provides customers financing alternatives through its finance operation, CarMax Auto Finance, as well as through its third-party financing providers. Further, it offers a range of other related products and services, including the sale of extended service plans, guaranteed asset protection, and accessories; the appraisal and purchase of vehicles directly from consumers; and vehicle repair services. As of December 21, 2011, the company operated 107 used car superstores in 52 markets. CarMax, Inc. was founded in 1993 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CarMax (NYSE: KMX  ) , whose recent revenue and earnings are plotted below.

• [By Jon C. Ogg]

  CarMax Inc. (NYSE: KMX) was downgraded to Neutral from Buy at Goldman Sachs.

  Carnival Corp. (NYSE: CCL) was downgraded to Underweight from Equal Weight at Morgan Stanley. The cruise line operator also was�downgraded to Neutral from Buy at Bank of America Merrill Lynch.

Hot High Tech Companies To Watch For 2014: M.D.C. Holdings Inc. (MDC)

M.D.C. Holdings, Inc., through its subsidiaries, engages in homebuilding and financial services businesses in the United States. Its homebuilding business activities include the purchase of finished lots or development of lots for the construction and sale of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company�s financial services business activities comprise the origination of mortgage loans primarily for homebuyers; provision of third-party insurance products to homebuyers; and title agency services to homebuyers in Colorado, Florida, Maryland, Nevada, and Virginia. It also provides insurance coverage on homes sold and for work performed in completed subdivisions; and re-insures the claims. M.D.C. Holdings, Inc. was founded in 1972 and is based in Denver, Colorado.

Advisors' Opinion:

• [By John Buckingham, Chief Investment Officer, Al Frank Asset Management, Inc. (AFAM)]

  MDC Holdings (MDC) is a builder and seller of homes in California, Colorado, Maryland, Virginia, Arizona, and Nevada under the name Richmond American Homes, and an originator of mortgage loans for home buyers.

Hot High Tech Companies To Watch For 2014: Scancell Holdings PLC (SCLP.L)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

Can U.S. Steel Catch Up to ArcelorMittal and Nucor?

U.S. Steel (NYSE: X  ) will release its quarterly report on Tuesday, and investors have hoped that the worst could be over for the steel industry. Yet even as rivals Nucor (NYSE: NUE  ) and ArcelorMittal (NYSE: MT  ) have seen some signs of relative strength, U.S. Steel recently had some bad news that could force it to play catch-up to participate in a long-awaited steel recovery.

U.S. Steel is just one of the companies that have gotten hit hard by the fall in global construction and infrastructure activity, with slowdowns in growth among emerging-market countries playing an especially big role in the drop in steel demand. Yet a big gain in sales of cars and trucks, along with a potential end to the recession in Europe, could give U.S. Steel avenues for greater sales growth. Yet can U.S. Steel ever regain the importance it once had and overshadow global industry giant ArcelorMittal and mini-mill specialist Nucor? Let's take an early look at what's been happening with U.S. Steel over the past quarter and what we're likely to see in its report.

Stats on U.S. Steel

Analyst EPS Estimate	($0.43)
Year-Ago EPS	$0.14
Revenue Estimate	$4.32 billion
Change From Year-Ago Revenue	(7.1%)
Earnings Beats in Past 4 Quarters	3

Source: Yahoo! Finance.

Why is U.S. Steel losing money?
In recent months, analysts have gotten much less enthusiastic about U.S. Steel earnings, doubling their loss projections for the third quarter and slashing their 2014 estimates by almost a third. The stock, though, has ignored those concerns, with shares rising 25% since late July.

U.S. Steel's second-quarter results showed the struggles that the steel industry has seen lately. Revenue fell almost 12% from the year-ago quarter, and the company lost money for the second quarter in a row. Furthermore, the company gave mixed guidance for the third quarter, expecting better results for its flat-rolled and tubular segment but worse results for its European segment because of a scheduled blast-furnace outage.

One big problem that U.S. Steel and ArcelorMittal in particular have had to deal with is the rise of Chinese steel production. State-run Chinese steelmakers have produced huge amounts of metal even as China's growth in steel use has slackened, putting pressure on global prices and making it far more difficult for ArcelorMittal to earn sales from the emerging-market nation. Even recent decisions from the Chinese government to cut steel production haven't yet caused a big positive impact for foreign companies, and U.S. Steel needs renewed demand without corresponding supply increases to boost global pricing to see its results improve.

More recently, some signs of a steel turnaround have emerged. The World Steel Association predicted that consumption would expand 2.9% this year, with Brazil and the rest of South America leading the way with expected jumps of more than 6% for the continent. Unfortunately, U.S. Steel isn't in the best position to profit directly from greater Latin American demand, as it has little production capacity outside the U.S. and therefore has to rely on secondary impacts in pricing to push profits higher. Even domestically, it has to fight Nucor's strong local presence, and that's a tough assignment given Nucor's highly successful business model that has allowed it to keep earning profits even under poor conditions.

Just a week ago, U.S. Steel said that it would have to take a charge of $1.8 billion against earnings to restate the value of its steel-production assets. The move reflects the ongoing problems in the industry, indicating that U.S. Steel believes the current value of the assets on its books is higher than their fair value.

In the U.S. Steel earnings report, watch to see how the company's guidance compares with what its peers are saying about the market. U.S. Steel needs an American economic recovery, and until it comes, the company could have trouble prospering.

These stocks should win in a recovery
U.S. Steel might be struggling, but with many global regions are still stuck in neutral, their resurgence could result in windfall profits for select companies. A recent Motley Fool report, "3 Strong Buys for a Global Economic Recovery," outlines three companies that could take off when the global economy gains steam. Click here to read the full report!

Click here to add U.S. Steel to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

10 Best Cheap Stocks To Watch For 2014

The number of companies paying dividends in the S&P 500 is at a 15-year high. According to FactSet, just over 80 companies in the index do not pay dividends. Paying dividends has become more attractive for companies of all sizes.

However, not all dividends are created equal. Of the 500 companies in the index, 99 pay their shareholders a dividend of 3% or more. By comparison, a 10-year Treasury note yields 2.66%. While Treasury securities come with an implied guarantee of a return of principal, share price appreciation of these companies also is expected to provide additional positive returns. Dividends are intended to make those returns even better over time.

BASEBALL: The priciest and cheapest playoff tickets

Dividends are considered among the most straightforward measures of capital returns. After all, they represent cash going back into the hands of investors directly from the company. However, a high dividend yield does not give a complete picture of the value of an investment. The health of the company also has to be considered. Investors need to be able to differentiate a high dividend from a safe dividend.

10 Best Cheap Stocks To Watch For 2014: Kohl's Corporation(KSS)

Kohl?s Corporation operates department stores in the United States. The company?s stores offer private and exclusive, as well as national branded apparel, footwear, and accessories for women, men, and children; soft home products, such as sheets and pillows; and housewares primarily to middle-income customers. As of January 29, 2011, it operated 1,089 stores in 49 states. The company also offers on-line shopping on its Web site at Kohls.com. Kohl?s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.

Advisors' Opinion:

• [By WALLSTCHEATSHEET.COM]

  Kohl�� is a department store retailer that operates locations across the United States. The company is reportedly getting ready to open three new stores, one of which will include an electric vehicle charging station. The stock has not made significant progress in recent years and is now trading near the top end of its range. Over the last four quarters, earnings and revenues have been rising. However, investors have had mixed feelings about recent earnings announcements. Relative to its peers and sector, Kohl’s has been a weak year-to-date performer. WAIT AND SEE what Kohl’s does at current prices.

• [By Paul Ausick]

  Wal-Mart Stores Inc. (NYSE: WMT), Macy�� Inc. (NYSE: M), Kohl�� Corp. (NYSE: KSS), and Nordstrom Inc. (NYSE: JWN) have all already reported poor quarterly results that barely met expectations in most cases. There�� no reason to expect anything substantially different this week, except perhaps from Home Depot, which has history of being cautious with its estimates.

• [By Ben Levisohn]

  JC Penney’s weakness is all its own. Macy�� (M) has gained 0.4% to $44.64, Sears�(SHLD) has risen 3.7% to $56.50 and Kohl���(KSS) has ticked down 0.1% to $53.90.

10 Best Cheap Stocks To Watch For 2014: Emerson Electric Company(EMR)

Emerson Electric Co. operates as a diversified manufacturing and technology company. The company engages in appliance solutions, climate technologies, industrial automation, motor technology, network power, process management, professional tools, and storage solutions businesses. Its appliance solutions business provides appliance controls, appliance motors, heating products, and white-rodgers; climate technology business provides heating, ventilation, air conditioning, and refrigeration (HVACR) solutions for residential, industrial, and commercial applications; and industrial automation business offers bearings and power transmission products, electrical power generation products, electric motors, variable speed drives and servos, electrical products, material joining solutions, fluid automation products, and wind turbine systems. The company?s motor technology business provides appliance motors, HVACR motors, DC motors, fractional horsepower motors, integral horsepower a nd larger motors, and drives; network power business provides power, precision cooling, connectivity, and embedded solutions; and process management business provides various wireless related products from self-organizing field networks to wireless asset and people tracking. Its professional tools business offers pipe working and threading equipment, pressing technology, utility locating and visual diagnostics systems, drain maintenance tools, power tools, air tools, general purpose hand tools, wet/dry vacs, job site storage equipment, truck tool boxes and equipment, and van storage equipment; and storage solutions business provides shelving and storage products for residential, commercial, and foodservice needs, as well as offers specialized carts, mobile computer workstations, and cabinet fixtures. The company was founded in 1890 and is headquartered in St. Louis, Missouri.

Advisors' Opinion:

• [By Lee Jackson]

  Rackspace Hosting Inc. (NYSE: RAX) recently added a huge new customer in Emerson Electric (NYSE: EMR). In January Emerson started using Rackspace to help tune and monitor climate control products for residential and commercial customers. Adoption has gone so well that Rackspace expects Emerson to hike its commitment from 43 servers today to 100 by year’s end. The consensus price target for the stock is posted at $52. The stock closed at $50.60.

• [By Dividends4Life]

  Related Articles:
  - People's United Financial Inc. (PBCT) Dividend Stock Analysis
  - Emerson Electric Co. (EMR) Dividend Stock Analysis
  - Archer Daniels Midland Company (ADM) Dividend Stock Analysis
  - AT&T Inc. (T) Dividend Stock Analysis
  - More Stock Analysis

• [By Vanin Aegea]

  The electronic components industry is one of the many industries hit by the economic recession. Growth for the short- and mid-term is very well limited by smaller disposable incomes. With a recovering economy, and the introduction of new technologies during the last decade, prospects for Emerson Electric (EMR) and Corning (GLW) defy a weak environment. Whether profits are on the way is the subject at hand. Let�� take a closer look.

• [By Chuck Saletta]

  Emerson Electric (NYSE: EMR  ) is a selection for the real-money Inflation-Protected Income Growth portfolio. Like any investment, it needs to be reviewed from time to time to see if it's still worth owning. In the brief video below, portfolio manager Chuck Saletta reviews its valuation, balance sheet, and dividends, and decides whether to hold on to the stock, or let it go.

10 Best China Stocks To Own For 2014: AeroVironment Inc.(AVAV)

AeroVironment, Inc. designs, develops, produces, and supports unmanned aircraft systems (UAS), and efficient energy systems for various industries and governmental agencies. Its UAS provide intelligence, surveillance, and reconnaissance, including real-time tactical reconnaissance, tracking, combat assessment, and geographic data to the small tactical unit or individual war fighter. The UAS wirelessly transmit critical live video and other information generated by their payload of electro-optical or infrared sensors directly to a hand-held ground control system, enabling the operator to view and capture images during the day or at night on a hand-held ground control unit. AeroVironment also provides spare equipment, alternative payload modules, batteries, chargers, repair services, and customer support for the UAS. In addition, the company produces industrial productivity and clean transportation solutions for commercial and government customers, develops potential clean t ransportation solutions, and performs contract engineering services; offers PosiCharge electric vehicle charging systems for industrial electric material handling fleets, electric vehicle charging systems for passenger and fleet vehicles, and power cycling and test systems for developers and manufacturers of plug-in electric and hybrid vehicles, as well as battery packs, electric motors, and fuel cells; and supplies power cycling and test systems to research and development organizations that focus on developing electric propulsion systems, electric generation systems, and electricity storage systems. It supplies its UAS primarily to the organizations within the United States department of defense. AeroVironment, Inc. was incorporated in 1971 and is headquartered in Monrovia, California.

Advisors' Opinion:

• [By Blake Bos]

  In the video below, Blake observes how smaller companies like iRobot� (NASDAQ: IRBT  ) and AeroVironment (NASDAQ: AVAV  ) , as well as huge defense contractors such as Lockheed Martin� (NYSE: LMT  ) and Northrop Grumman� (NYSE: NOC  ) , are positioned to benefit from this trend.

• [By Roberto Pedone]

  One aerospace player that insiders are loading up on here is AeroVironment (AVAV), which is engaged in the design, development, production and support of unmanned aircraft systems and efficient energy systems for various industries and governmental agencies. Insiders are buying this stock into decent strength, since shares are up 23% during the last six months.

  AeroVironment has a market cap of $504 million and an enterprise value of $379 million. This stock trades at a premium valuation, with a trailing price-to-earnings of 108.75 and a forward price-to-earnings of 44.35. Its estimated growth rate for this year is 47.4%, and for next year it's pegged at 82.1%. This is a cash-rich company, since the total cash position on its balance sheet is $128.81 million and its total debt is zero.

  A director just bought 5,000 shares, or about $112,000 worth of stock, at $22.50 per share.

  From a technical perspective, AVAV is currently trending right below its 50-day moving average and above its 200-day moving averages, which is neutral trendwise. This stock has been trending sideways for the last two months, with shares moving between $20.78 on the downside and $23.97 on the upside. Shares of AVAV are now starting to trend within range of triggering a breakout trade above the upper-end of its recent sideways trading chart pattern.

  If you're bullish on AVAV, then look for long-biased trades as long as this stock is trending above support at $22.30 or above its 200-day at $21.05 and then once it breaks out above some near-term overhead resistance levels at $23.60 to $23.97 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 205,927 shares. If that breakout triggers soon, then AVAV will set up to re-test or possibly take out its next major overhead resistance levels at $25 to $28 a share.

10 Best Cheap Stocks To Watch For 2014: Cowen Group Inc.(COWN)

Cowen Group, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides alternative investment management, investment banking, research, and sales and trading services for its clients. It manages separate client focused portfolio through its subsidiaries. Through its subsidiaries, the firm invests in equity and fixed income markets. It also invests in alternative investments markets through its subsidiaries. Cowen Group, Inc. was founded in 1994 and is based in New York, New York with additional offices in Boston, Massachusetts, Chicago, Illinois, Cleveland, Ohio, Dallas, Texas, and San Francisco, California.

10 Best Cheap Stocks To Watch For 2014: USG Corporation(USG)

USG Corporation, through its subsidiaries, engages in the manufacture and distribution of building materials worldwide. The company offers gypsum and related products, including gypsum wallboard, joint compounds used for finishing wallboard joints, cement boards, glass mat sheathing, gypsum fiber panels, poured gypsum underlayments, ultra light panels, and various construction plaster products. Its gypsum products are used in various building applications to finish the interior walls, ceilings, and floors in residential, commercial, and institutional constructions, and repair and remodel constructions. The company also produces gypsum-based products for agricultural and industrial customers to use in various applications, including soil conditioning, road repair, fireproofing, and ceramics. In addition, it manufactures ceiling grid and acoustical ceiling tile for electrical and mechanical systems, and air distribution and maintenance applications. USG Corporation distribut es its gypsum products through specialty wallboard distributors, building materials dealers, home improvement centers and other retailers, contractors, and a network of distributors. Further, it distributes other manufacturers? gypsum wallboard, joint compound and other gypsum products, as well as drywall metal, insulation, and roofing products and accessories. The company sells its products under SHEETROCK, DUROCK, FIBEROCK, SECUROCK, LEVELROCK, RED TOP, IMPERIAL, DIAMOND, SUPREMO, AURATONE, ACOUSTONE, DONN, DX, FINELINE, CENTRICITEE, CURVATURA, and COMPASSO brands. The company was founded in 1901 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Eric Volkman]

  She also serves as chairman of the United States Steel and Carnegie Pension Fund, and on that organization's investment committee. Outside of U.S. Steel, she sits on the board of directors of USG (NYSE: USG  ) and the Pennsylvania Business Council, among other entities.

• [By Seth Jayson]

  USG (NYSE: USG  ) reported earnings on April 24. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), USG missed estimates on revenues and missed estimates on earnings per share.

10 Best Cheap Stocks To Watch For 2014: Sirius XM Radio Inc.(SIRI)

Sirius XM Radio Inc. provides satellite radio services in the United States and Canada. It broadcasts a programming lineup of approximately 135 channels of commercial-free music, sports, news and information, talk and entertainment, traffic, and weather on subscription fee basis through two satellite radio systems in the United States; and holds an interest in the satellite radio services offered in Canada. The company also simulcasts music and selected non-music channels over the Internet; and offers applications to allow consumers to access its Internet services on mobile devices. As of December 31, 2010, it had 20,190,964 subscribers. In addition, the company designs, establishes specifications, sources or specifies parts and components, and manages various aspects of the logistics and production of satellite radios; licenses its technology to various electronics manufacturers to develop, manufacture, and distribute radios under various brands; and imports radios distri buted through its Websites. The company?s satellite radios are primarily distributed through automakers, retailers, and its Websites. Further, it provides music services for commercial establishments; a satellite television service to offer music channels as part of certain programming packages on the DISH Network satellite television service; music and comedy channels to mobile phone users through mobile phone carriers; Backseat TV, a service offering television content designed primarily for children in the backseat of vehicles; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and real-time traffic and weather services. The company was formerly known as Sirius Satellite Radio Inc. and changed its name to Sirius XM Radio Inc. in August 2008. Sirius XM Radio Inc. was founded in 1990 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Rick Munarriz]

  If you're wondering who will pay to install monitors for every seat you may have missed the Wi-Fi component here. Unlike JetBlue -- which has seatback monitors delivering 36 DirecTV (NASDAQ: DTV  ) television channels and most of Sirius XM's (NASDAQ: SIRI  ) satellite radio stations, but is late to the game by just now starting to update its fleet for Wi-Fi -- Southwest won't be providing monitors. Passengers will use their Wi-Fi tablets, laptops, and smartphones to log into the Web-based service that DISH has been advertising in recent months.

10 Best Cheap Stocks To Watch For 2014: Popular Inc.(BPOP)

Popular, Inc., through its subsidiaries, provides a range of retail and commercial banking products and services primarily to corporate clients, small and middle size businesses, and retail clients in Puerto Rico and Mainland United States. It offers deposit products; commercial, consumer, and mortgage loans, as well as lease finance; and finance and advisory services. The company also offers trust and asset management, brokerage and investment banking, and insurance and reinsurance services. As of December 31, 2010, it owned and occupied approximately 94 branch premises and other facilities in Puerto Rico; and 119 offices, including 20 owned and 99 leased in New York, Illinois, New Jersey, California, Florida, and Texas. Popular, Inc. was founded in 1917 and is headquartered in San Juan, Puerto Rico.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Popular (NASDAQ: BPOP) shares tumbled 5.54 percent to $27.48 after Morgan Stanley downgraded the stock from Equal-weight to Underweight.

  Pacific Coast Oil Trust (NYSE: ROYT) down, falling 7.13 percent to $16.70 after the company priced a public offering by Pacific Coast Energy Company LP and other selling unitholders of 13,500,000 trust units at a price of $17.10 per unit.

10 Best Cheap Stocks To Watch For 2014: Lattice Semiconductor Corporation(LSCC)

Lattice Semiconductor Corporation designs, develops, manufactures, and markets programmable logic products and related software. The company offers field programmable gate array (FPGA) products, including LatticeECP family for deployment in wireless infrastructure and wireline access equipment, as well as in video and imaging applications; and LatticeXP for the security, surveillance, and display markets. It also provides programmable logic device (PLD) products comprising various versions of ispMACH4000 in-system programmable complex programmable logic device family; MachXO family that is designed for a range of low density applications; platform manager, power manager, and ispClock programmable mixed signal devices; and software development tools and intellectual property cores. The company sells its products directly to end customers through a network of independent manufacturers? representatives and indirectly through a network of independent sell-in and sell-through distributors. It primarily serves original equipment manufacturers in the communications, computing, consumer, industrial, military, automotive, and medical end markets. The company was founded in 1983 and is headquartered in Hillsboro, Oregon.

Advisors' Opinion:

• [By Lee Jackson]

  Lattice Semiconductor Corp. (NASDAQ: LSCC) is a top chip stock to buy at Jefferies. The company announced last month three new complete reference designs that will make it easier for electronic OEMs to deliver media-rich experiences to their end users by taking advantage of low-cost, industry-standard MIPI (Mobile Industry Processor Interface) camera, application processor and display technologies. The Jefferies price objective for the stock is $6.50, and the consensus is also at $6.50. Lattice closed yesterday at $4.63.

10 Best Cheap Stocks To Watch For 2014: Ur Energy Inc(URG)

Ur-Energy Inc., an exploration stage junior mining company, engages in the identification, acquisition, evaluation, exploration, and development of uranium mineral properties. The company has 13 projects located in Wyoming and Nebraska, the United States; and 3 exploration projects located in the Northwest Territories and Nunavut, Canada. Its landholdings cover approximately 90,000 acres in the United States and approximately 140,000 acres in Canada. The company was founded in 2004 and is headquartered in Littleton, Colorado.

Advisors' Opinion:

• [By John Udovich]

  Since the start of the week, small cap nuclear fuel stock USEC Inc (NYSE: USU) more than doubled for investors, something that has not happened for investors in uranium stocks like Uranium Resources, Inc (NASDAQ: URRE), Denison Mines Corp (NYSEMKT: DNN), Ur-Energy Inc. (NYSEMKT: URG) and Uranerz Energy Corp (NYSEMKT: URZ). To recap: USEC Inc closed at the $6 level on Friday, but then it surged to the $15 level on Monday only to open at the $10 level on Tuesday when it ultimately closed at $12.46. So what in the world is going on with USEC Inc and is it time to revisit nuclear fuel and uranium stocks?

• [By The Energy Report]

  JH: There are several companies that are in production that we follow in the U.S., such as Cameco Corp. (CCJ). Cameco produces at the Smith Ranch-Highland in the Powder River Basin. There's Uranium One, also in the Powder River Basin. There's Uranium Energy Corp. (UEC). A few near-term producers are rapidly coming online. Ur-Energy Inc. (URG) is one company we like in Wyoming.

10 Best Cheap Stocks To Watch For 2014: Kimber Resources Inc(KBX)

Kimber Resources Inc., a junior mineral resource company, engages in the acquisition, exploration, and development of mineral resource properties in Mexico. The company primarily explores for gold and silver deposits. Its principal property includes the Monterde Property, which consists of 35 mineral concessions totaling approximately 29,296 hectares located in the Sierra Madre mountains of southwestern Chihuahua State. Kimber Resources Inc. was founded in 1995 and is headquartered in Vancouver, Canada.

When Value Investing Fails

Though I am definitely a value investing advocate, there are simply times when basic value concepts like fair value and margin of safety fail to provide useful conclusions in analysis. Case in point: the valuation of a fast-growing business like LinkedIn (NYSE: LNKD  ) . To illustrate, I'll attempt to find LinkedIn's fair value and its margin of safety.

Meteoric growth is hard to estimate
LinkedIn's first-quarter revenue increased by 72% from the year-ago quarter. That's impressive. Yet it presents a serious problem for value investors.

Value investors, of course, seek out the intrinsic value of a business. And forecasting growth rates for the business going forward is central to any valuation of an ongoing business. But LinkedIn's current high growth rates make forecasting the next several years very difficult. High growth rates present investors with extremely high levels of uncertainty. Difficult questions arise: When will the decline in growth rates begin? To what degree will it unfold? The answers to these two questions will drastically affect valuation.

Sure, year-over-year revenue growth rates have topped 85% in each of the past three years, making LinkedIn's high growth rates pretty consistent. But this doesn't mean we can expect revenue to grow by exceptional rates over the next several years, or even next year for that matter.

For instance, in each of the last three years, Apple's (NASDAQ: AAPL  ) revenue and EPS year-over-year growth rates topped 44%. But in the trailing 12 months, EPS is up only 1.8% from the year before. Who could have seen that coming? Apple shares have fallen right along with growth rates, trading more than 40% lower than they were about nine months ago. Apple is no longer a growth stock. In fact, at today's prices, it could make an excellent value investing candidate or even be considered a worthy dividend stock.

What is LinkedIn worth?
Ignoring the notion that growth stocks are tough to value, let's give LinkedIn a proper shot at a valuation.

Consider two different scenarios. In Scenario A, LinkedIn manages to increase free cash flow by 50% next year, followed by growth rates that decelerate by about 10% annually for the next nine years.

Year

Growth Rate

1	50%
2	45%
3	40.5%
4	36.5%
5	32.8%
6	29.5%
7	26.6%
8	23.9%
9	21.5%
10	19.4%

Given these assumptions, a discounted cash flow valuation yields a fair value of about $197 for LinkedIn shares, giving shares about an 11% margin of safety at today's price around $177.

But in Scenario B, things don't go quite as well. Free cash flow growth rates decelerate by 15% every year.

Year

Growth Rate

1	50%
2	42.5%
3	36.1%
4	30.7%
5	26.1%
6	22.2%
7	18.9%
8	16%
9	13.6%
10	11.6%

This scenario also seems realistic. Yet now investors face a conundrum. If a scenario like this unfolds, a better estimate of the fair value of LinkedIn's shares is $132, based on a discounted cash flow valuation. In other words, shares would be about 33% overvalued at today's price.

We could also explore a Scenario C, in which growth rates in excess of 40% are sustained for more than five years. In this case, LinkedIn shares would be grossly undervalued.

Herein lies the problem with applying the concepts of value investing to stocks like LinkedIn. Slight changes in estimated growth rates for these fast-growing companies present an uncomfortably wide range of fair value estimates, leaving value investors with nothing more than a headache.

Another approach
So does this mean stocks like LinkedIn do not make the grade as an investment? Not necessarily. Another way to add some context to the stock is to look at the company's addressable market.

LinkedIn's largest operating segment, recruiting, accounts for about 57% of revenue. And fortunately for investors, the segment is plush with opportunity. There's an estimated field of 200,000 corporate clients, and only about 18,000 use LinkedIn. Its recruiting segment already appears to be on a path of massive market share gains, with the segment's revenue up 80% in the first quarter of 2013 from the year-ago quarter.

In other words, LinkedIn's addressable market is huge.

Be flexible
Does LinkedIn's huge addressable market imply the stock is undervalued? No, but it does present a new way to look at its opportunities.

We have to face the fact that there's just no excellent way to find the fair value of the shares of fast growing companies like LinkedIn. Investors brave enough to put their money in these stocks should do so only with a very strong conviction of the company's competitive advantage and its addressable market. A plan to hold for a very long time is essential because the astronomic valuations pinned to stocks like these will most likely be accompanied by very volatile price swings.

Top 5 Biotech Stocks To Own For 2014

Typical value investing methods may not always work. Even when they don't, there's no reason to turn a cold shoulder on a stock. Instead, change your approach and tread carefully.

This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table -- and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

 

Best Gold Companies To Invest In Right Now

Prices of platinum (PTM) and palladium (PALL) continue to outperform other metals such as gold (GLD), silver (SLV) and copper (JJC) over the past 9 months. For many months, I have been warning my readers about the growing risks to platinum and palladium supply as labor strikes intensify in South Africa.

(click to enlarge)

Some of the largest platinum and palladium producers in South Africa are suffering from the labor disputes and violence. South Africa accounts for close to three quarters of the world's platinum supply.

I do not believe that long-term solutions will be worked out there between the unions and the mining companies. Some of the miners have settled but it comes with increasing costs to miners who are already barely marginable.

The risks to disruptions in production are just too great for new capital going into South Africa mines. Once production is disrupted and the deep underground mines are closed it is very difficult and costly to restart.

Best Gold Companies To Invest In Right Now: Newmont Mining Corporation(Holding Company)

Newmont Mining Corporation, together with its subsidiaries, engages in the acquisition, exploration, and production of gold and copper properties. The company?s assets or operations are located in the United States, Australia, Peru, Indonesia, Ghana, Canada, New Zealand, and Mexico. As of December 31, 2009, it had proven and probable gold reserves of approximately 93.5 million equity ounces and an aggregate land position of approximately 27,500 square miles. The company was founded in 1916 and is headquartered in Greenwood Village, Colorado.

Best Gold Companies To Invest In Right Now: First Majestic Silver Corp.(AG)

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties with a focus on silver in Mexico. The company owns interests in La Encantada Silver Mine comprising 4,076 hectares of mining rights and 1,343 hectares of surface land located in Coahuila; La Parrilla Silver Mine consisting of mining concessions covering an area of 69,867 hectares; and San Martin Silver Mine comprising approximately 7,841 hectares of mineral rights and approximately 1,300 hectares of surface land rights located in Jalisco. It also holds interests in Del Toro Silver Mine consisting of 393 contiguous hectares of mining claims and an additional 129 hectares of surface rights located in Zacatecas; Real de Catorce Silver Project comprising 22 mining concessions covering 6,327 hectares located in San Luis Potosi state; and Jalisco Group of Properties consisting of mining claims totalling 5,240 hectares located in Jalisco. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Doug Ehrman]

  While many precious-metals companies have been in a slump of late, there is one that belongs perpetually in your portfolio: Silver Wheaton (NYSE: SLW  ) . The company is not like other miners -- including Pan American Silver (NASDAQ: PAAS  ) and First Majestic (NYSE: AG  ) -- in that it has a unique business plan that insulates it against many of the vagaries of the mining business. Moreover, because silver will always have a significant industrial demand component, even with the heightened volatility you see in the silver market, maintaining exposure to silver is appropriate.

• [By Doug Ehrman]

  Despite the weakness seen in precious metals a few weeks ago, silver has been relatively stable ever since mid-April, with the iShares Silver Trust (NYSEMKT: SLV  ) trading in a dollar-wide range ever since. With the presidents of the Chicago and Philadelphia Federal Reserve banks��releasing conflicting statements, turmoil may be just around the corner. Miners like Pan American (NASDAQ: PAAS  ) and First Majestic (NYSE: AG  ) are still facing operating challenges, while silver streaming darling Silver Wheaton (NYSE: SLW  ) struggles as well.

• [By Doug Ehrman]

  It is no secret that precious metals companies have been taking a pounding for some time now. The SPDR Gold Trust (NYSEMKT: GLD  ) and iShares Silver Trust (NYSEMKT: SLV  ) , the gold and silver ETFs, have been hard hit and operating companies like First Majestic (NYSE: AG  ) and Barrick Gold (NYSE: ABX  ) have been hit even harder. Through all of these struggles, and in some cases because of them, one precious metals company continues to look attractive for the long term: Silver Wheaton (NYSE: SLW  ) .

Top Dividend Stocks To Invest In Right Now: Thompson Creek Metals Company Inc.(TC)

Thompson Creek Metals Company Inc., through its subsidiaries, engages in mining, milling, processing, and marketing molybdenum products in the United States and Canada. The company?s principal properties include the Thompson Creek Mine and mill in Idaho; a metallurgical roasting facility in Langeloth, Pennsylvania; and a joint venture interest in the Endako Mine, mill, and roasting facility in British Columbia. It also holds interests in development projects comprising the Davidson molybdenum property and the Berg copper-molybdenum-silver property located in northern British Columbia; the Howard?s Pass property, a lead and zinc project situated in the Yukon territory-northwest territories border; and the Maze Lake property, a gold project located in the Kivalliq district of Nunavut. The company produces molybdenum products, primarily molybdic oxide and ferromolybdenum, as well as soluble technical oxide, pure molybdenum tri-oxide, and high purity molybdenum disulfide. As o f December 31, 2010, its consolidated recoverable proven and probable ore reserves totaled 462.2 million pounds of contained molybdenum in the Thompson Creek Mine and the Endako Mine. The company was formerly known as Blue Pearl Mining Ltd. and changed its name to Thompson Creek Metals Company Inc. in May 2007. Thompson Creek Metals Company Inc. is based in Denver, Colorado.

Advisors' Opinion:

• [By Selena Maranjian]

  The biggest new holdings are Chesapeake Energy�puts, and shares of Discovery Communications. Other new holdings of interest include Halcon Resources (NYSE: HK  ) , and Thompson Creek Metals (NYSE: TC  ) . Oil and gas company Halcon, operating in the promising Bakken region, as well as Texas's productive Eagle Ford shale region, among others, is expected to grow by 30% annually over the coming years. It recently reported 2012 net daily production 128% higher than year-ago levels, and proven reserves up 417%. Halcon was recently one of my colleague Joel South's top two energy holdings, and analysts at Stifel recently upped its rating�from Hold to Buy.

Best Gold Companies To Invest In Right Now: CME Group Inc.(CME)

CME Group Inc. operates the CME, CBOT, NYMEX, and COMEX regulatory exchanges worldwide. The company provides a range of products available across various asset classes, including futures and options on interest rates, equity indexes, energy, agricultural commodities, metals, foreign exchange, weather, and real estate. It offers various products that provide a means of hedging, speculation, and asset allocation relating to the risks associated with interest rate sensitive instruments, equity ownership, changes in the value of foreign currency, credit risk, and changes in the prices of commodities. CME Group owns and operates clearing house, CME Clearing, which provides clearing and settlement services for exchange-traded contracts and counter derivatives transactions; and also engages in real estate operations. Its primary trade execution facilities consist of its CME Globex electronic trading platform and open outcry trading floors, as well as privately negotiated transact ions that are cleared and settled through its clearing house. In addition, the company offers market data services comprising live quotes, delayed quotes, market reports, and historical data services, as well as involves in index services business. CME Group?s customer base includes professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, and governments. It has strategic partnerships with BM&FBOVESPA S.A., Bursa Malaysia Derivatives, Singapore Exchange Limited, Green Exchange, Dubai Mercantile Exchange, Johannesburg Stock Exchange, and Bolsa Mexicana de Valores, S.A.B. de C.V., as well as joint venture agreement with Dow Jones & Company. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group was founded in 1898 and is headquartered in Chicago, Illinois.

Advisors' Opinion:

• [By Holly LaFon]

  Within equities, we believe that most companies will be negatively impacted by rising interest rates, but we did identify some exceptions. For example, the CME Group is a Chicago-based operator of numerous trading exchanges including a large volume of 铿�ed income futures contracts. Higher interest rates and greater interest rate volatility tends to be a catalyst for greater trading volumes, and hence, greater revenue for CME (CME). The company was our top-performing U.S. investment in the last three months with gains of nearly 30%. The insurance industry is another area that we believe can offer resilience in the face of rising rates. This quarter we added to our positions in Manulife Financial in Canada, AmTrust Financial in the U.S., and introduced U.K.-based Aon to our international portfolio. Many of our insurance companies enjoyed strong performance this quarter and helped offset the declines suffered within the 铿�ed income portfolio.

• [By Mark Thompson]

  The Chicago Mercantile Exchange (CME), which operates the world's biggest derivatives market, is asking investors to stump up more cash to trade in financial products that provide protection against rising interest rates.

• [By Steve Sears]

  Shares of Nasdaq OMX Group have gained 0.4% to $30.58 today, while CME Group (CME) has fallen 1.1% to $71.89, IntercontinentalExchange (ICE) has dropped 0.2% to $185.16, and NYSE Euronext (NYX) has ticked down 0.1% to $42.66.

• [By Roberto Pedone]

  One financial market player that's starting to move within range of triggering a major breakout trade is CME Group (CME), which offers products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. This stock has been in play with the bulls so far in 2013, with shares up sharply by 48%.

  If you take a look at the chart for CME Group, you'll notice that this stock recently formed a triple bottom chart pattern at $70.42, to $69.88 and $70.28 a share. Following that bottom, shares of CME have now started to trend back above its 50-day moving average of $72.70 a share. That move is quickly pushing CME within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in CME if it manages to break out above some near-term overhead resistance levels at $75.50 to $77.65 a share and then once it clears its 52-week high at $79.45 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.84 million shares. If that breakout hits soon, then CME will set up to enter new 52-week-high territory above $79.45, which is bullish technical price action. Some possible upside targets off that breakout are $90 to $100 a share.

  Traders can look to buy CME off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $72.70 a share or just below more support at $70 a share. One can also buy CME off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Best Gold Companies To Invest In Right Now: Australian Dollar(AU)

AngloGold Ashanti Limited primarily engages in the exploration and production of gold. It also produces silver, uranium oxide, and sulfuric acid. The company conducts gold-mining operations in South Africa; continental Africa, including Ghana, Guinea, Mali, Namibia, and Tanzania; Australia; and the Americas, which include Argentina, Brazil, and the United States. It also has mining or exploration operations in the Democratic Republic of the Congo, Guinea, and Colombia. As of December 31, 2010, the company had proved and probable gold reserves of 71.2 million ounces. The company has a strategic alliance with Thani Dubai Mining Limited to explore, develop, and operate mines across the Middle East and parts of North Africa. AngloGold Ashanti Limited, formerly known as Vaal Reefs Exploration and Mining Company Limited, was founded in 1944 and is headquartered in Johannesburg, South Africa.

Advisors' Opinion:

• [By Dan Caplinger]

  One way Yamana has kept its competitive cost advantage is through extensive sales of base-metal byproducts like copper and zinc, as both it and fellow low-cost rival Goldcorp (NYSE: GG  ) benefit from utilizing those secondary metals to offset the cost of their gold production. Peers Gold Fields (NYSE: GFI  ) and AngloGold Ashanti (NYSE: AU  ) , on the other hand, face much higher costs in part because of their exposure to South Africa and its unstable labor market.

• [By Dan Caplinger]

  We've seen the flip side of that trend play out in recent years, as rock-bottom interest rates in the U.S. have encouraged investment in higher-yielding income investments in places like Australia, Brazil, and South Africa. Interest from foreign investors got to be so extensive in Brazil that the federal government imposed a tax on foreign investors in bonds in order to curb demand and slow the pace of the Brazilian real's appreciation. Exchange-rate issues also likely played a role in the health of the commodities markets, as mining giants BHP Billiton (NYSE: BHP  ) and Rio Tinto (NYSE: RIO  ) in Australia benefited from increased demand largely for base metals. Similarly, South African gold miners AngloGold Ashanti (NYSE: AU  ) and Gold Fields (NYSE: GFI  ) outperformed rivals from elsewhere in the world, benefiting from strength in the South African rand currency.

• [By Rich Duprey]

  Considering the work stoppages and violent clashes that have become the norm at South African precious-metals mines, perhaps the miners were wondering exactly what they were getting for their money. An expose by South Africa's Daily Maverick has uncovered a system where miners such as AngloGold Ashanti (NYSE: AU  ) and BHP Billiton (NYSE: BHP  ) surreptitiously paid for the salaries of the heads of the local mining unions to keep the mine workers in line, and it's only because the miners sought to end the "uncomfortable arrangement" with the unions that the matter came to light.

• [By Dan Caplinger]

  But even bigger damage came from gold-mining stocks. AngloGold Ashanti (NYSE: AU  ) has lost almost 60% of its value in 2013, with the drop in gold prices having an outsized impact on the gold miner's prospects. AngloGold has also suffered from investors moving away from emerging markets like South Africa in favor of U.S. stocks, as fears of the Federal Reserve's exit from its quantitative easing program have reduced overall risk tolerance among many investors.

Best Gold Companies To Invest In Right Now: Northgate Minerals Corporation(NXG)

Northgate Minerals Corporation, together with its subsidiaries, engages in exploring, developing, processing, and mining gold and copper deposits in Canada and Australia. Its principal producing assets include 100% interests in the Fosterville and Stawell Gold mines in Victoria, Australia; and the Kemess South mine located in north-central British Columbia, Canada. The company was formerly known as Northgate Exploration Limited and changed its name to Northgate Minerals Corporation in May 2004. Northgate Minerals Corporation was founded in 1919 and is headquartered in Toronto, Canada.

Best Gold Companies To Invest In Right Now: Goldcorp Incorporated(GG)

Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. It produces and sells gold, silver, copper, lead, and zinc. The company was founded in 1954 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Ben Levisohn]

  Newmont has dropped 2.2% to $25.73 at 3:02 p.m. While that’s in-line with the Market Vectors Gold Miners ETF’s (GDX) 2.2% fall to 23.03, it’s better than the most heavily traded gold-mining stocks. Shares of Barrick Gold (ABX), for instance, have dropped 3.6% to $17.20, Gold Corp (GG) is down 3.1% at $23.54 and Eldorado Gold (EGO) has declined 3.9% to $5.82.

• [By Doug Ehrman]

  Due to gold's recent plunge marking its largest percentage drop since 1980, the explosive volume in the SPDR Gold Trust (NYSEMKT: GLD  ) , and many swirling global macroeconomic factors, the precious yellow metal has spooked investors. The decline has not been limited to the commodity, as miners like Goldcorp (NYSE: GG  ) , Barrick Gold (NYSE: ABX  ) , and Newmont Mining (NYSE: NEM  ) are experiencing precipitous declines as well. Adding to the concern is the fact that investors have been unable to pinpoint the precise cause of the collapse.

• [By Matt DiLallo]

  If the closure of the world's largest gold mine does to prove to be a catalyst, a low-cost gold miner like GoldCorp (NYSE: GG  ) �would be a beneficiary. The company has low cash costs, which has led to higher margins than its peers. Any boost in the price of gold due to the mine's closure will help pad GoldCorp's bottom line.

Best Gold Companies To Invest In Right Now: Claude Resources Inc.(CGR)

Claude Resources Inc. engages in the acquisition, exploration, and development of precious metal properties, as well as production and marketing of minerals in Canada. It primarily explores for gold in northern Saskatchewan and northwestern Ontario. The company holds interests in the Seabee gold mine located at Laonil Lake, northern Saskatchewan; and the Madsen property that consists of 6 contiguous claim blocks totaling approximately 10,000 acres, located in the Red Lake Mining District of northwestern Ontario. It also holds interest in the Amisk Gold project, which covers an area of 13,800 hectares in the province of Saskatchewan. The company was founded in 1980 and is based in Saskatoon, Canada.

Top 5 Biotech Stocks To Own For 2014

The market has soared to begin 2013 with many biotech companies leading the way. That should be no surprise given the massive swings that companies can make in just a week's time. Unfortunately, some biotech stocks have also lagged the returns of the broader market. In the following video, Fool contributor Maxx Chatsko reviews the five coldest biotech stocks through the first five months of the year and tells investors if things are about to get better any time soon. Not all laggards are created equal.

Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy by clicking here now.

Top 5 Biotech Stocks To Own For 2014: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

Advisors' Opinion:

• [By Bryan Murphy]

  The difference between Growlife's leadership and, say that of competitors like Cannabis Science Inc. (OTCMKTS: CBIS) or Medical Marijuana Inc. (OTCMKTS: MJNA), has been relatively well documented here at the SmallCap Network site. I think the way I - well, someone else - put it back on June 25th says it best...."Growlife is sort of the demure girl in the corner who doesn't do shots off her navel in the bar." It may not have sizzle, but it does have substance.

• [By John Udovich]

  Although its summer, there has been a steady stream of good news about medical marijuana even though important small cap marijuana stocks�Medical Marijuana Inc (OTCMKTS: MJNA) and Cannabis Science Inc (OTCMKTS: CBIS) have been fairly quietly lately while Growlife Inc (OTCBB: PHOT), a more indirect play on the spread of legalized marijuana, has produced�some news for investors:

Top 5 Biotech Stocks To Own For 2014: Vertex Pharmaceuticals Incorporated(VRTX)

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Ben Levisohn]

  Acorda has dropped 6.3% to $33.12 today at 2pm, while MannKind has gained 5.1% to $5.37. Vertexs Pharmaceuticals (VRTX) has gained 3.3% to $73.25, Celldex Therapeutics (CLDX) has jumped 2.4% to $27.86 and Gilead Sciences (GILD) has ticked up 0.8% to $63.18.

• [By Dan Carroll]

  Good was the opposite of Vertex Pharmaceuticals' (NASDAQ: VRTX  ) week, as shares of the firm fell 8.8% over the past five days. Vertex scored big back in 2011 with the approval of its hepatitis-C drug Incivek, but that therapy's reliance on an injectable combination therapy has set back the drug's progress as all-oral hep-C medications have become all the rage. Vertex is working on its own all-oral therapy, VX-135.

• [By Brian Orelli]

  Investors should also watch Johnson & Johnson's hepatitis C drug Incivo that the health-care giant sells abroad for Vertex Pharmaceuticals (NASDAQ: VRTX  ) . Even though it has to ship some of the profits to Vertex, Incivo is a moneymaker because doctors in Europe haven't started cutting back on prescribing the drug while they wait for next-generation hepatitis C drugs as they have in the U.S., where it's called Incivek.

• [By Alex Dumortier, CFA]

  The 60% return that Vertex Pharmaceuticals (NASDAQ: VRTX  ) achieved in a single day last month on the test results of a cystic-fibrosis drug is the sort of thing that gets investors' salivary glands flowing. (This is not an illiquid micro-cap stock, by the way; with a market capitalization that exceeds $17 billion, Vertex is a large-cap issue.)

Top 10 Cheap Stocks To Invest In 2014: ARIAD Pharmaceuticals Inc.(ARIA)

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company?s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and non-small cell lung cancer. Its product pipeline also includes ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. In addition, the company focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. Further, it licenses its ARGENT cell-sign aling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products, and to conduct drug discovery research. The company has collaboration and license agreements with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent restenosis of injured vessels. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Brian Orelli]

  The other downside of this investment strategy is that it's not always clear when a decision will happen. Recently, the FDA has been making decisions well ahead of the goal set by the Pharmaceutical Drug User Fee Act, commonly referred to as the PDUFA date. ARIAD Pharmaceuticals� (NASDAQ: ARIA  ) , for instance, gained early approval for its leukemia drug Iclusig last year, and shares traded down by double digits after the widely expected announcement.

Top 5 Biotech Stocks To Own For 2014: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By Debra Fiakas]

  Earlier this month biotech Dendreon (DNDN) announced the approval in the European Union of its only commercial product Provenge. Aimed at prostate cancer, Provenge is a novel therapeutic based on Dendreon's proprietary cellular immunotherapy technology. The good news could not have come at a better time. Dendreon has had Provenge on the market in the U.S. since spring 2010. While sales have ramped impressively to $304.3 million in the most recently reported twelve months, the top-line has failed to cover costs and expenses.

• [By Paul Ausick]

  Stocks on the move: Facebook Inc. (NASDAQ: FB) is up 5.2% at $40.63, a new 52-week high, on a positive note from analysts at J.P. Morgan. Dendreon Corp. (NASDAQ: DNDN) down 9.1% at $2.90 after posting a new 52-week low of $2.85.

• [By Sean Williams]

  In order to do their best to conserve cash leading up into the full implementation of the bill, I wouldn't be surprised to see insurers denying or declining to pick up the tab on what they deem overpriced procedures. Not to pick on Intuitive Surgical again, but the company did mention, "a trend by payers toward encouraging conservative management and treatment in outpatient settings." Another potential victim here is Dendreon (NASDAQ: DNDN  ) , whose cellular immunotherapy known as Provenge that's used to treat advanced prostate cancer costs $93,000 annually. By comparison, Johnson & Johnson's�Zytiga costs just $5,500 per month ($66,000 annually) and would be the better cost-effective choice for insurers, potentially leaving Provenge out in the cold.

• [By Keith Speights]

  Let's look at an example of a hypothetical investor we'll call Joe. In April 2010, Joe saw that the Food and Drug Administration approved a new prostate cancer vaccine, Provenge, which was developed by Dendreon (NASDAQ: DNDN  ) . Provenge looked very promising, with one prominent analyst forecasting peak annual sales as high as $4 billion.

Top 5 Biotech Stocks To Own For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By Keith Speights and Max Macaluso, Ph.D.]

  Which biotech stocks should investors take a hard look at buying now? Health care analyst Max Macaluso sat down with Fool.com contributor Keith Speights recently to find out which stocks he likes in the biotech sector. Two big biotechs that Keith recommends are�Biogen Idec (NASDAQ: BIIB  ) and Celgene (NASDAQ: CELG  ) .�

• [By Keith Speights]

  Currently, the top 10 stocks in which the ETF is invested comprise more than 55% of total assets. Sure, there are some speculative names included in the full list of holdings. However, the largest stakes are in big biotechs with long track records, like Gilead Sciences (NASDAQ: GILD  ) , Celgene (NASDAQ: CELG  ) , Amgen (NASDAQ: AMGN  ) , and Biogen Idec (NASDAQ: BIIB  ) . These top four holdings make up almost one-third of the ETF's total assets.

• [By Keith Speights]

  If it could get past regulators' antitrust concerns, Celgene (NASDAQ: CELG  ) would be a good fit to buy Onyx. Celgene already dominates the multiple myeloma market with Revlimid. Pomalyst, which was approved by the FDA earlier this year, competes against Onyx' Kyprolis as third-line and fourth-line treatments for the blood disease. Celgene's sales force would be able to easily merge Kyprolis into the rest of the company's product lineup.